Serevent Asthma Safety Signal Is Good News For Advair, GSK Says

Adverse event outcomes from a Serevent safety study could help GlaxoSmithKline in one of its key messages for Advair, CEO J.P. Garnier told analysts in New York City Feb. 13

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet